Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components

about

Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components

Item

http://www.wikidata.org/entity/Q35658766

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Bifunctional μ/δ opioid peptid ...... connecting the two components

@ast

Bifunctional μ/δ opioid peptid ...... connecting the two components

@en

type

Item

label

Bifunctional μ/δ opioid peptid ...... connecting the two components

@ast

Bifunctional μ/δ opioid peptid ...... connecting the two components

@en

prefLabel

Bifunctional μ/δ opioid peptid ...... connecting the two components

@ast

Bifunctional μ/δ opioid peptid ...... connecting the two components

@en

P1476

Bifunctional μ/δ opioid peptid ...... connecting the two components

@en

P2093

Carole Lemieux

http://www.w3.org/2001/XMLSchema#string

Jinguo Ding

http://www.w3.org/2001/XMLSchema#string

Nga N Chung

http://www.w3.org/2001/XMLSchema#string

Peter W Schiller

http://www.w3.org/2001/XMLSchema#string

P2860

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Bi- or multifunctional opioid peptide drugs.

The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists.

Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series

Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone).

Development of potent μ and δ opioid agonists with high lipophilicity.

A new example of a morphine-sensitive neuro-effector junction: adrenergic transmission in the mouse vas deferens

Designed multiple ligands. An emerging drug discovery paradigm.

Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1).

Unsulfated C-terminal 7-peptide of cholecystokinin: a new ligand of the opiate receptor.

P304

186-193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1747-0285.2011.01268.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51787606

http://www.w3.org/2001/XMLSchema#string

P698

22070627

http://www.w3.org/2001/XMLSchema#string

P932

3253174

http://www.w3.org/2001/XMLSchema#string